Showing 1 - 6 results of 6 for search 'Jelle O. Barentsz', query time: 0.03s Refine Results
  1. 1
    Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection

    Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection by Bas Israël, Gerjon Hannink, Jelle O. Barentsz, Marloes M.G. van der Leest

    Published 2022-09-01
    Get full text
    Article
  2. 2
    Intranodal signal suppression in pelvic MR lymphography of prostate cancer patients: a quantitative comparison of ferumoxtran-10 and ferumoxytol

    Intranodal signal suppression in pelvic MR lymphography of prostate cancer patients: a quantitative comparison of ferumoxtran-10 and ferumoxytol by Oscar A. Debats, Ansje S. Fortuin, Hanneke J.M. Meijer, Thomas Hambrock, Geert J.S. Litjens, Jelle O. Barentsz, Henkjan J. Huisman

    Published 2016-10-01
    Get full text
    Article
  3. 3
    Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI

    Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI by Peter F. A. Mulders, Jack A. Schalken, Jelle O. Barentsz, J. P. Michiel Sedelaar, Jurgen J. Futterer, Inge M. van Oort, Elisabeth A. Wierenga, Gisele H. J. M. Leyten

    Published 2013-05-01
    Get full text
    Article
  4. 4
    Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

    Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer by Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Gerty Schreibelt, Mark A. J. Gorris, Niven Mehra, Michiel Simons, Anna L. de Goede, Michelle M. van Rossum, Alexandra J. Croockewit, Carl G. Figdor, J. Alfred Witjes, Erik H. J. G. Aarntzen, Roel D. M. Mus, Mareke Brüning, Katja Petry, Martin Gotthardt, Jelle O. Barentsz, I. Jolanda M. de Vries, Winald R. Gerritsen

    Published 2019-11-01
    Get full text
    Article
  5. 5
    Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

    Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial by Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah

    Published 2020-09-01
    Get full text
    Article
  6. 6
    Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial

    Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial by Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Willemijn A. van Gemert, Michel de Groot, Harm Westdorp, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah

    Published 2021-11-01
    Get full text
    Article

Search Tools: